Pharmacology and clinical experience with risperidone

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 7, 2000, Pages 1441-1453

  Love, Raymond C ^a   Nelson, Matthew W ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Antipsychotic; Atypical; Psychophamwcology; Risperidone; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

CLINICAL TRIAL; HUMAN; PSYCHOSIS; REVIEW;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; HUMANS; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 0034569872     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.7.1441     Document Type: Article

References (64)

1. CARPENTER VT, BUCHANAN RV: Medical progress: Schizophrenia. Ar. Engl.J. Med. (1994) 330(10):681-690.
2. ALVIR JM, LIEBERMAN JA, SAFFERMAN AZ et al.: Clozapine-induced agranulocytosls. Incidence and risk factors hi the United States. A'. Etigl.J. Med. (1993) 329(3):l62-l67.
3. KANE J, HONIGFELD G, SINGER J, MELTZER H: Clozapine for the treatment-resistant schizophrenic. A doubleblind comparison with chlorpromazlne. Arch. Gen. PycbiatiyWSS) 45(9):789-796.
4. HENDERSON DC, CAGLIERO E, GRAY C ctal.-. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five-year naturalistic study. Am.J. Psychiatry (2000) 157(6)-.975-981.
5. KANE JM: Drug therapy: Schizophrenia. Ar. Engl.J. Med. (1996) 334(0:34-41.
6. MELTZER HY, MATSUBARA S, LEE J-C: The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotic drugs. Psycbopharmacol. Bull. (1989) 25:390-392.
7. LEYSEN JE, JANSSEN PM, MEGENS AA, SCHOTTE A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile and pharmacologie activity. J. Clin. Psychiatry (1994) 55(SuppI.):5-12.
8. Risperdal (risperidone) full prescribing information. (1999) Janssen Pliarmaceutica, Titusville, NJ, USA.
9. KAPUR S, ZIPURSKY RB, REMINGTON G: Clinical and theoretical implications of 5-HT2 and Dz receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am. ]'. Psychiatry (1999) 156(2):2S6-293.
10. KLEINBERG DL, DAVIS JM, DE COSTER R, VAN BAELEN B, BRECHER M: Prolactin levels and adverse events in patients treated with risperidone. / Clin. Psychopharmacol. (1999) 19U):57-6l.
11. RICHELSON E: Receptor pharmacology of neurolcptics: relation to clinical effects. J. Clin. Psychiatry 60(Suppl. 10):5-14.
12. HUANG ML, VAN PEER A, WOESTENBORGHS R et al.: Pharniacokinctics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Phannacol. Ther. 54(3):257-26S.
13. HEYKANTS J, HUANG ML, MANNENS G et al.: The pharmacokinetics of risperidone in humans: a summary.J. Clin. Psychiatry(1994) 55(Suppl.):13-17.
14. VAN BEIJSTERVELDT LE, GEERTS RJ, LEYSEN JE et al.: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopbannacology (1994) 114(1):53-02.
15. MARDER SR, MEIBACH RC: Risperidone in the treatment of schizophrenia. Am.J. Psychiatry(1994) 151:825-835. A large, multicentre trial.
16. CHOUINARD G, JONES B, REMINGTON G et al.: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. (1993) 13:25-40. A large, multicentre trial.
17. LOVE RC, CONLEY RR, KELLY DL, BARTKO JJ: A dose-outcome analysis of risperidone. J. Clin. Psychiatry (1999) 60(ll):771-775.
18. KLIESER E, LEHMANN E, KINZLER E et a!.: Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J. Clin. Psycbophannacol. (1995) 15(Suppl. 1):45S-51S.
19. PEUSKENS J: Risperidone in the treatment of chronic schizophrenia: a multi-national, multi-centre, doubleblind, parallel group study versus haloperidol. Br. J. Psychiatry (1995) l66(6):712-726. A large, multicentre trial.
20. CONLEY RR, MAHMOUD R, RISPERIDONE STUDY GROUP: Risperidone versus olanzapine in patients with schizophrenia and schizoafective disorder. American College of Xeuropsychopbannacology Annual Meeting. Acapulco, Mexico (1999).
21. HO BC, MILLER D, NOPOULOS P, ANDREASEN NC: A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J. Clin. Psychiatrytiy?)) 60(10):658-663-
22. MÜLLEN J, REINSTEIN M, BARI M et al.: Quetiapine and risperidone in outpatients with psychotic disorders: results of the QUEST trial. 37tb Animal Meeting of the American College of Neuropsychopharmacology. Las Croabas, Puerto Rico (1998).
23. CSERNANSKY J, OKAMOTO A, BRECHER M: Risperidone vs. haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: a long-term double-blind comparison. 54lb Annual Scientific Convention of the Society of Biological Psychiatry. Washington DC, USA (1999).
24. BERSANI G, BRESA GM, MECO G et al.: Combined serotonin-5HT2 and dopamine-Dz receptor antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R64766). Hum. Psychophannacol. (1990) 5:225-231.
25. MESOTTEN F, SUY E, PJETQUIN M, BURTON P, HEYLEN S, GELDERS Y: Therapeutic effect and safety of Increasing doses of risperidone (R64766) in psychotic patients. Psycbopharmacology (1989) 99:445-449.
26. DESSEILLES M, ANTOINE J, PIETQUIN M et al.: Risperidone in psychotic patients: an open dose-finding study. Psychiatry Psychobiol. (1990) 5:319-324.
27. GELDERS YG, HEYLEN SL, VANDEN BUSSCHE G, REYNTJENS AJ, JANSSEN PA: Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry(.1990) 23:206-211.
28. CASTELÄO JF, FERREIRA L, GELDERS YG, HEYLEN SLE: The efficacy of the Dj and 5HT2 receptor antagonist risperidone (R64766) in the treatment of chronic psychosis: an open dose-finding study. Schizophr. Res. (1989) 2:411-415.
29. MÖLLER HJ, PELZER E, KISSLING W, RIEHL T, WERNICKE T: Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. Pbarmacopsycbiatry(.199') 24:185-189.
30. MECCO G, BEDINI L, BINIFATI V, SONSINI U: Risperiddnc in the treatment of chronic schizophrenia with tardive dyskinesia: a single-blind crossover study versus placebo. Cwr. Thcr. Res. (1989) 46:876-883.
31. BORISON RL, PATHIRAJA AP, DIAMOND BI, MEIBACH RC: Risperidone: clinical safety and efficacy in schizophrenia. Psychophannacol. Bull. (1992) 28:213-218.
32. CLAUS A, BOLLEN J, DECUYPER H et al.: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta. Psychiatrica Scand. (1992) 85(4):295-305.
33. EMSLEY R, RISPERIDONE WORKING GROUP: Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Scbiz. Bull. (1999) 25(4):721-729.
34. TRAN PV, HAMILTON SH, KUNTZ AJ et al: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic I disorders./ Clin. Psycbophannacol. (1997) 17:407-418. I
35. SCHOOLER MR: Comments on article by Tran and colleagues, 'Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.' / Clin. Psychopharmacol. (1998) 18:174-175.
36. GHEUENS J, GREBB JA: Comments on article by Tran and colleagues, 'Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.' / Clin. Psychophannacol. (1998) 18:176-177.
37. TOLLEFSON GD, TRAN PV: Reply - letter to the editor. J Clin. Psychophannacol. (1998) 18:175-176.
38. TOLLEFSON GD, TRAN PV: Reply - letter to the editor. Clin. Psychophannacol. (1998) 18:177-178.
39. PURDON SE, JONES BD, ST1P E et al.: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidoL Arch. Gen. Psychiatry (2000) 57(3):249-258.
40. BONDOLFI G, DUFOUR H, PATRIS M et al.: Risperidone versus clozapinc in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am. J. Psychiatry (.y)8) 155(4):499-504.
41. WIRSHING DA, MARSHALL BD JR, GREEN MF et al.: Risperidone in treatment-refractory schizophrenia. Am.]. Psychiatry (.1999) 156(9): 1374-1379-
42. SACHS G, RISPERIDONE BIPOLAR STUDY GROUP: Safety and efficacy of risperidone vs. placebo as add-on therapy to mood stabilizers in the treatment of manic phase of bipolar disorder. 4tib Annual NCDEU Meeting. Boca Raton, Florida, USA (2000).
43. VIETA E, GASTO C, COLOM F, MARTINEZ A, OTERO A, VALLEJO J: Treatment of refractory rapid cycling bipolar disorder with risperidone.J. Clin. Psychopharmacol. (1998) 18(2):172-174.
44. SEGAL J, BERK M, BROOK S: Risperidone compared with both lithium and haloperidol in mania: a doubleblind randomized controlled trial. Clin. Nenropharmacol. (1998) 21(3):176-180.
45. KATZ IR, JESTE DV, MINTZER JE, CLYDE C, NAPOLITANO J, BRECHER M: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. / Clin. Psycbialry (1999) 60(2):107-115. First well controlled study of an SGA in dementia.
46. DE DEYN PP, RABHERU K, RASMUSSEN A et al.: A randomized trial of risperidone, placebo and haloperidol for behavioral symptoms of dementia. Neurology (1999) 53(5):946-955.
47. TOREN P, LAOR N, WEIZMAN A: Use of atypical neurolcptics in child and adolescent psychiatry./ Clin. Psychiatry (1998) 59(12):644-656.
48. FINDLING RL, MAXWELL K, WIZNITZER M: An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol. Bull. (1997) 33(D:155-159.
49. NICOLSON R, AVAD G, SLOMAN L: An open trial of risperidone in young autistic children. J. Am. Acad. Child Adotesc. Psychiatry'(1998) 37(4):372-376.
50. SCHREIER HA: Risperidone for young children with mood disorders and aggressive behavior. J. Child Adolesc. Psychopharmacol. (1998) 8(l):49-59.
51. BUITELAAR JK: Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior./ Child Adolesc. Psychopharmacol. (2000) 10(l):19-26.
52. NYBERG S, ERIKSSON B, OXENST1ERNA G, HALLD1N C, FARDE L: Suggested minimal effective dose of risperidone based on PET-measured D2 and S-HTiA receptor occupancy in schizophrenic patients. Am.]. Psychiatry (1999) 156(6):869-875.
53. JESTE DV, LACRO JP, BAILEY A, ROCKWELL E, HARRIS MJ, CALIGIURI MP: Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients.J. Am. Gerialr. Soc. (1999) 47:716-719.
54. BRECHER M, OKAMATO A, NAPOLITANO J, KANE JM: Follow-up study of risperidone hi the treatment of patients with dementia: very low incidence of emergent tardive dyskinesia and reduction in severity of preexisting dyskinesia. 37 Annual Meeting of the American College of Ncnropsychopharmacology. Las Croabas, Puerto Rico (1998).
55. CARACCI G, ANANTHAMOORTHY R: Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. J. Clin. Psychopharmacol. (1999) 19(2):194-196.
56. HENDERSON DC, CAGLIERO E, BORBA CP et al.: Atypical antipsychotic agents and glucose metabolism: Bergman's MINMOD analysis. 40th Annual iCDEU Meeting. Boca Raton, Florida, USA (2000).
57. WIRSHING DA, ERHART SM, PIERRE JM et al.: Non-extrapyratnldal side effects of novel antipsychotics. Ciirr. Opin. Psychiatry (2000) 13(1):45-50.
58. ALLISON DB, MENTORE JL, HEO M et al.-. Antipsychoticinduced weight gain: a comprehensive research synthesis. Am.J. Psychiatry (1999) 156(ll):l68o-l696. A meta-analysis comparison of weight gain with SGAs.
59. KELLY DL, CONLEY RR, LOVE RC, HORN DS, USHCHAK CM: Weight gain in adolescents treated with risperidonc and conventional antipsychotics over six months. J. Child Adolesc. Psychopharmacol. (1998) 8(3):151-159.
60. FOSTER RH, GOA KL: Risperidone: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics (1998) 14(1):97-133.
61. LOVE RC, CONLEY RR, KELLY DL, BARTKO JJ: A comparison of rehospitalization rates between patients treated with atypical antipsychotics and those treated with depot antipsychotics [abstract]. Schiz. Res. (1999) 36:345.
62. CHOUINARD G, ALBRIGHT PS: Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidoLJ. Clin. Psychopbannacol. (1997) 17(4):298-307.
63. OH P, EINARSON TR, ISKEDIJAN M et al.: Pharmacoeconomic evaluation in schizophrenia: clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Canadian Office for Health Technology Assessment (1997).
64. EERDEKENS M, RASMUSSEN M, VERMEULEN A, LOWENTHAL R, VAN PEER A: Kinetics and safety of a novel risperidone depot formulation. 4Cfb Annual KCDEU Meeting. Boca Raton, Florida, USA (2000).